Lebrikizumab After Multiple Prior Advanced Therapies in Moderate‐To‐Severe Atopic Dermatitis: A Real‐World Case Series

Documenti analoghi

• Reply to Hagino et al.: ‘Importance of Upadacitinib dose escalation prior to switch to lebrikizumab’
  di: Luigi Gargiulo, et al.
  Pubblicazione: (2025)
• Long‐Term Treatment With Systemic Rifampicin and Clindamycin for Epidermal Growth Factor Receptor Inhibitor‐Related Acneiform and Mucocutaneous Rash: A Valid Therapeutic Option
  di: Giovanni Paolino, et al.
  Pubblicazione: (2025)
• Real‐World Effectiveness and Safety of Lebrikizumab in Moderate‐to‐Severe Atopic Dermatitis: A Multicenter Study From Spain
  di: Jose Carlos Armario‐Hita, et al.
  Pubblicazione: (2025)
• Immune cutaneous reactions in orf and in pseudocowpox viruses: clinicopathologic correlations and management to avoid misdiagnosis
  di: Giovanni Paolino, et al.
  Pubblicazione: (2024)
• Erythroderma in the spectrum of thymoma‐associated multiorgan autoimmunity (TAMA) syndrome: a case report of a patient with thymoma and myasthenia gravis
  di: Matteo Bianco, et al.
  Pubblicazione: (2024)